Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces HbA1c (up to 2.6%) and body weight (up to 12.9 kg) in Type 2 Diabetes patients, outperforming existing GLP-1 agonists and insulin.
Tirzepatide is a once-weekly injectable medication for Type 2 Diabetes that works by mimicking two gut hormones (GIP and GLP-1). It is highly effective at lowering blood sugar and promoting significant weight loss, often outperforming other common diabetes medications. Patients should expect a gradual dose increase to minimize stomach upset, and pharmacists play a key role in managing side effects and ensuring adherence.
Across SURPASS-1 to SURPASS-6 trials, tirzepatide consistently achieved greater reductions in HbA1c (up to − 2.6%) and body weight (up to − 12.9 kg) compared with placebo, semaglutide, or insulin comparators
Why this rating
Based on multiple large-scale randomized controlled trials (SURPASS series) and observational cohorts.
Source
Revolutionizing type 2 diabetes management: the role of the pharmacist in unlocking the potential of tirzepatide
David Banji et al. · Saudi Pharmaceutical Journal · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →